
For patients battling late-stage lung cancer, prospects for survival have improved significantly since the advent of medications known as immune checkpoint inhibitors. But exactly how long patients with advanced non-small cell lung cancer (NSCLC) need to be on immunotherapy has not been known. Until now. According to new research involving more than 1,000 patients, those… read on > read on >